In the same trial, CHF patients with increased disease severity, based on the aforementioned criteria, were able to mobilise CD34+/CD133+/KDR+ EPCs as well as compared to the group with reduced disease severity (Kourek et al. 2020b). The gene discussed is CD34; the disease is congestive heart failure.